The metabolic consequences of IDO1 activity (e.g., low tryptophan and high kynurenine) suppress the activity of T cells through a variety of mechanisms and may also limit the efficacy of immunotherapy in GBM. The gene discussed is IDO1; the disease is glioblastoma.